SCHEMBL19087000

SCHEMBL19087000

COCOc1cc(C)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.34
ACHE P22303 1/20 0.33
HIF1A Q16665 1/20 0.33
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
ALOX12 P18054 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
EGFR P00533 1/20 0.31
UCHL1 P09936 1/20 0.31
LPL P06858 1/20 0.30
LIPG Q9Y5X9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22320285 0.88 ACHE (0.33) CSF1RACHEHIF1AMEN1USP2
SCHEMBL10076681 0.87 L3MBTL1 (0.39) CSF1RHIF1AMEN1USP2ALDH1A1
SCHEMBL21410221 0.84 EGFR (0.39) EGFRUCHL1
SCHEMBL2280832 0.84 SNCA (0.38) HIF1AALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL31652177 0.84 LPL (0.40) EGFRLPLLIPG
SCHEMBL30973537 0.84 EGFR (0.39) EGFRUCHL1
SCHEMBL3804868 0.83 SNCA (0.37) HIF1AALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL3804866 0.83 SNCA (0.37) HIF1AALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL15334799 0.83 ACHE (0.47) CSF1RACHEMEN1USP2ALDH1A1
SCHEMBL22712518 0.82 EGFR (0.43) HIF1AALDH1A1MAPTMAPK1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116969920-A Fused pyridazine derivative, preparation method and medical application thereof 上海辉启生物医药科技有限公司 2023-10-31 CN disclosed
EP-3921311-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163647-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed
US-10562858-B2 Crystalline anti-trichophyton agents and preparation process thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-18 US disclosed
US-20170233346-A1 CRYSTALLINE ANTI-TRICHOPHYTON AGENTS AND PREPARATION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
EP-3190105-A1 CRYSTALLINE ANTI-TRICHOPHYTON DRUG AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2017-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562858-B2 Crystalline anti-trichophyton agents and preparation process thereof ZP1, TBKBP1, MITF CSF1R 3176/4885ACHE 4734/4885HIF1A 2682/4885
US-20170233346-A1 CRYSTALLINE ANTI-TRICHOPHYTON AGENTS AND PREPARATION PROCESS THEREOF ZP1, TBKBP1, MITF CSF1R 3176/4885ACHE 4734/4885HIF1A 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.